FY2025 EPS Estimates for Exelixis Reduced by Leerink Partnrs

Exelixis, Inc. (NASDAQ:EXEL) – Equities research analysts at Leerink Partnrs dropped their FY2025 earnings per share (EPS) estimates for shares of Exelixis in a research report issued on Wednesday, February 5th. Leerink Partnrs analyst A. Berens now forecasts that the biotechnology company will post earnings per share of $2.10 for the year, down from their prior estimate of $2.15. The consensus estimate for Exelixis’ current full-year earnings is $1.74 per share.

Several other research analysts have also weighed in on the company. BMO Capital Markets lowered Exelixis from an “outperform” rating to a “market perform” rating and boosted their price target for the stock from $36.00 to $40.00 in a research report on Friday, December 20th. JMP Securities reiterated a “market outperform” rating and issued a $41.00 price objective on shares of Exelixis in a report on Thursday, January 23rd. Morgan Stanley raised shares of Exelixis from an “equal weight” rating to an “overweight” rating and lifted their target price for the stock from $30.00 to $40.00 in a report on Monday, January 27th. Oppenheimer cut shares of Exelixis from an “outperform” rating to a “market perform” rating and reduced their target price for the company from $41.00 to $33.00 in a research report on Friday, January 24th. Finally, Wells Fargo & Company increased their target price on shares of Exelixis from $32.00 to $36.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 30th. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $36.06.

Exelixis Stock Up 0.1 %

NASDAQ EXEL opened at $33.50 on Monday. Exelixis has a 12-month low of $20.01 and a 12-month high of $37.59. The firm’s 50 day moving average is $34.35 and its 200-day moving average is $30.64. The company has a market capitalization of $9.57 billion, a PE ratio of 21.47, a price-to-earnings-growth ratio of 0.63 and a beta of 0.53.

Hedge Funds Weigh In On Exelixis

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Los Angeles Capital Management LLC grew its stake in shares of Exelixis by 124.0% in the third quarter. Los Angeles Capital Management LLC now owns 1,790,855 shares of the biotechnology company’s stock worth $46,473,000 after purchasing an additional 991,494 shares during the last quarter. Allspring Global Investments Holdings LLC lifted its holdings in Exelixis by 82.1% during the 4th quarter. Allspring Global Investments Holdings LLC now owns 1,562,790 shares of the biotechnology company’s stock worth $52,884,000 after buying an additional 704,786 shares during the period. Globeflex Capital L P grew its position in shares of Exelixis by 203.8% in the 4th quarter. Globeflex Capital L P now owns 975,151 shares of the biotechnology company’s stock valued at $32,473,000 after buying an additional 654,200 shares during the last quarter. Caisse DE Depot ET Placement DU Quebec acquired a new stake in shares of Exelixis in the third quarter valued at about $14,979,000. Finally, Raymond James Financial Inc. bought a new position in shares of Exelixis during the fourth quarter worth about $17,046,000. 85.27% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Exelixis

In other news, EVP Jeffrey Hessekiel sold 60,000 shares of the company’s stock in a transaction that occurred on Friday, November 29th. The stock was sold at an average price of $36.67, for a total value of $2,200,200.00. Following the completion of the transaction, the executive vice president now owns 486,059 shares of the company’s stock, valued at $17,823,783.53. This represents a 10.99 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, EVP Patrick J. Haley sold 10,000 shares of Exelixis stock in a transaction that occurred on Friday, November 22nd. The stock was sold at an average price of $35.27, for a total transaction of $352,700.00. Following the sale, the executive vice president now owns 278,665 shares in the company, valued at approximately $9,828,514.55. This represents a 3.46 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 111,588 shares of company stock valued at $3,981,864 in the last quarter. Insiders own 2.85% of the company’s stock.

Exelixis Company Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.